Abstract
Abstract 19
Despite great progress in embryogenesis, the underlying mechanism that controls tissues and organs size remains a mystery. We previously showed that transplanted pig embryonic tissues are markedly enlarged in Factor VIII knockout (F8KO) mice, and identified a regulatory role for thrombin. Here, we describe a novel potential pathway through which coagulation factors might regulate size control of the hematopoietic system.
The hematopoietic stem cell (HSC) pool of F8KO mice exhibited instability manifested by three parameters: 1) Reduced proportion of CD34low cells within the Lin−Sca+Kit+ (LSK) progenitors. Median CD34 staining of F8KO LSK cells was 40±4% higher compared to WT controls (n=8 mice, p<0.001). 2) Reduced long term repopulating capacity measured by competitive transplantation. While 6 weeks post transplantation of F8KO or WT BM similar chimerism levels were found, markedly reduced F8KO donor chimerism levels were detected at 22 weeks (22.2±4.4% vs 38.9±9.9%; p=0.008). 3) Hyper responsiveness to G-CSF. We used G-CSF to reveal pre-existing abnormalities in the HSC pool. G-CSF treated F8KO mice exhibited significantly enlarged spleens compared to WTs (256±149mg, n=25 vs 181±61mg, n=32; p=0.01). This difference was corrected upon F8 treatment. We further used splenectomized mice to test the effect of G-CSF on BM alone. The LSK cell number in the peripheral blood (PB) of G-CSF treated splenectomized F8KO mice was 3 fold higher compared to WT splenectomized mice (380±127 cells/ml, n=3 vs 64±6 cells/ml, n=3, P=0.01).
Since factor VIII has no known physiological function other than in coagulation, it was tempting to assume that down-stream coagulation factors, in particular thrombin, are responsible for the observed distorted HSC regulation. Indeed, F8KO mice exhibit a 2 fold decrease in peak plasma thrombin concentration compared to WT mice. Furthermore, thrombin receptor 1 knockout mice (PAR1 KO), exhibited enhanced responsiveness to G-CSF, with higher PB LSK cell numbers compared to WT mice (766±180 cells/ml, n=7 vs 489±189 cells/ml, n=5; p<0.005). Likewise, G-CSF induced splenomegaly and LSK mobilization were enhanced in WT mice upon treatment with thrombin inhibitors such as Clexane and Dagibitran, or by the PAR1 antagonist, palmitoylated peptide (pal-RCLSSSAVANRS).
To investigate the thrombin site of action, a reciprocal transplantation was performed. Interestingly, chimeras generated by transplantation of WT BM into PAR1KO recipients showed enhanced responsiveness to G-CSF compared to WT recipients. Thus, chimeras lacking PAR1 on their stroma cells only, were more prone to induced splenomegaly than controls (114.4±26.4mg; n=10, vs 162.6±19.34mg; n=5; p<0.003). A less dramatic but significant enhancement was observed in WT recipients of PAR1 KO BM, lacking PAR1 on their hematopoietic cells (141.4±23.5mg, n=10, p=0.026). Our results suggest that thrombin-PAR1 signalling in BM stromal cells has a predominant role in regulating HSC maintenance.
Taken together, these results show a critical and novel role for the coagulation cascade, in part via the Thrombin/PAR1 axis, in regulating the reciprocal interplay between the dynamic bone structure and HSC maintenance and mobilization. While further studies in Hemophilia are warranted, our new insights also suggest that thrombin inhibitors such as Clexane and Dabigatran could potentially enhance HSC mobilization in G-CSF treated donors and increase the number of cells harvested.
No relevant conflicts of interest to declare.
Author notes
Asterisk with author names denotes non-ASH members.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal